ABT-263

ABT-263 

To Order Contact us: caitlyn@ucb-bioproducts.com

ABT-263 (Navitoclax)
A3007-50 50 mg
EUR 282
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)
A3007-S Evaluation Sample
EUR 81
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT
B7737-5.1 10 mM (in 1mL DMSO)
EUR 108

ABT
B7737-50 50 mg
EUR 125

Sulfo-Cyanine 3 NHS ester
263 10 mg
EUR 480

ABT-737
2463-25
EUR 675

ABT-737
2463-5
EUR 207

ABT-869
1615-1
EUR 213

ABT-869
1615-5
EUR 615

ABT-888
1620-1
EUR 218

ABT-888
1620-5
EUR 615

ABT-494
B1947-25
EUR 892

ABT-494
B1947-5
EUR 262

ABT-072
HY-101634 10mg
EUR 1399

ABT-239
HY-12195 10mg
EUR 337

ABT-751
HY-13270 50mg
EUR 394

ABT-046
HY-15197 10mM/1mL
EUR 420

ABT-670
HY-19483 1mg
EUR 849

ABT-639
HY-19721 100mg
EUR 2943

ABT-737
HY-50907 10mM/1mL
EUR 155

ABT-737
E1KS1002 5mg
EUR 521

ABT-751
E1KS1165 10mg
EUR 521

ABT-492
E1KS1553 5mg
EUR 1111

Abt-869
20-abx182361
  • EUR 1803.00
  • EUR 551.00
  • 100 mg
  • 10 mg

Abt-199
abx184638-1g 1 g
EUR 648

ABT-737
A8193-10 10 mg
EUR 154
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737
A8193-100 100 mg
EUR 606
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737
A8193-5 5 mg
EUR 108
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737
A8193-5.1 10 mM (in 1mL DMSO)
EUR 148
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737
A8193-50 50 mg
EUR 398
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737
A8193-500 500 mg
EUR 1558
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737
A8193-S Evaluation Sample
EUR 81
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-199
A8194-1 1 mg
EUR 131
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199
A8194-5 5 mg
EUR 270
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199
A8194-5.1 10 mM (in 1mL DMSO)
EUR 421
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199
A8194-50 50 mg
EUR 838
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199
A8194-500 500 mg
EUR 1442
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199
A8194-S Evaluation Sample
EUR 81
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-639 hydrochloride
HY-101616 20mg
EUR 13439

ABT-702 dihydrochloride
HY-103161 100mg
EUR 1313

Linifanib (ABT-869)
E1KS1003 5mg
EUR 521

ABT-888 (Veliparib)
E1KS1004 5mg
EUR 325

Lopinavir(ABT-378)
E1KS1380 10mg
EUR 403

Paritaprevir(ABT-450)
20-abx184297
  • EUR 1247.00
  • EUR 913.00
  • 10 mg
  • 5 mg

ABT-751 (E7010)
A1493-10 10 mg
EUR 148
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)
A1493-100 100 mg
EUR 595
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)
A1493-5.1 10 mM (in 1mL DMSO)
EUR 177
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)
A1493-50 50 mg
EUR 432
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

Linifanib (ABT-869)
A2949-100 100 mg
EUR 780
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)
A2949-25 25 mg
EUR 328
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)
A2949-5 5 mg
EUR 142
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)
A2949-5.1 10 mM (in 1mL DMSO)
EUR 195
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

ABT-888 (Veliparib)
A3002-10 10 mg
EUR 148
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)
A3002-200 200 mg
EUR 835
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)
A3002-5 5 mg
EUR 125
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)
A3002-5.1 10 mM (in 1mL DMSO)
EUR 160
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-263

Site Title, Some rights reserved.

Terms of Use - Privacy Policy

WordPress Di Blog Theme